
- English
- ePUB (mobile friendly)
- Available on iOS & Android
About this book
High-level commentary on various facets of the pharmaceutical industry from a key leader in the field
This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.
Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:
- Fiscal consequences of curing hepatitis C
- mRNA vaccines and the race for a cure
- Why the government does not deserve a piece of Biopharma's profits
- Paying for drugs whose ultimate value is unknown
- The impact of reduced revenues on R&D
This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
Frequently asked questions
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Information
Table of contents
- Cover
- Table of Contents
- Title Page
- Copyright Page
- Dedication
- ACKNOWLEDGMENTS
- INTRODUCTION
- CHAPTER 1: THE $1000 PILL
- CHAPTER 2: ENTER THE PAYERS
- CHAPTER 3: PANDEMIC
- CHAPTER 4: FEDERAL INVESTMENT IN R&D
- CHAPTER 5: INSULIN
- CHAPTER 6: THE COSTLY ALZHEIMER’S DISEASE DRUG
- CHAPTER 7: GENE THERAPY
- CHAPTER 8: PROVING THE VALUE OF EXPENSIVE DRUGS
- CHAPTER 9: GENERIC DRUGS
- CHAPTER 10: ABOUT THOSE SOARING PHARMA PROFITS
- CHAPTER 11: SCHEMES TO LOWER DRUG PRICES
- FINAL THOUGHTS
- Index
- End User License Agreement